Evolus’ injectable neurotoxin, Jeuveau, which was approved in 2019 and rivals AbbVie's major blockbuster Botox, knows exactly what it is. It’s an aesthetic product and that’s all it wants to be: no ...

Crows' feet, frown lines, and forehead creases are all signs of a life full of facial expressions. And while some may be reminders of happy memories, it's also totally fine to want to smooth them away ...

Evolus is shaking up promotion of its Botox rival. The old campaign was supporting above-market growth of wrinkle-busting product Jeuveau, but Evolus wants more, leading it to launch new branding ...

Evolus, Inc., a pharmaceutical company specializing in aesthetic products, faces significant challenges with its lead product Jeuveau, a treatment for frown lines. Jeuveau's undifferentiated clinical ...

When it comes to a scraped knee, you probably reach for a Band-Aid. Sneeze attack? Kleenex, please! Sometimes a brand is so good, so ubiquitous, that it defines an industry. The same could be said for ...

Company launches bold rebrand of Jeuveau® (prabotulinumtoxinA-xvfs), a modern-made neurotoxin dedicated exclusively for aesthetics Jeuveau® has been the fastest-growing neurotoxin in the U.S. for two ...

Please provide your email address to receive an email when new articles are posted on . New phase 2 results showed 40 units of Jeuveau sustained improvements in glabellar lines up to 6 months. Adverse ...

“Extra-strength” 40U formulation demonstrated a duration of 26 weeks, or 6 months, when measuring the time for a patient to return back to their baseline Glabellar Line score after a single treatment ...

The US neurotoxin market is rapidly growing, and Evolus has a strong position in the market, especially among younger, aesthetically-oriented consumers. The global market for non-invasive aesthetic ...

When I say I’ve been getting Botox my entire adult life, I’m not exaggerating one bit—I started at the ripe, young age of 19 to help prevent wrinkles from forming, and I’ve honestly never looked back.